title: Prevalence of use of cardiovascular drugs in 499 patients with suspected coronary artery disease at time of hospitalization for coronary angiography and in 357 patients with obstructive coronary artery disease documented by coronary angiography.
abstract: In a prospective study of 499 patients with suspected coronary artery disease (CAD) hospitalized for coronary angiography, the prevalence of use of cardiovascular drugs at hospital admission was 80% for antiplatelet drugs, 66% for beta blockers, 55% for angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), 65% for lipid-lowering drugs, 24% for calcium channel blockers (CCBs), and 16% for nitrates. In 357 patients with obstructive CAD diagnosed by coronary angiography, the prevalence of use of these drugs at hospital discharge was 100% for antiplatelet drugs, 97% for beta blockers, 91% for ACE inhibitors or ARBs, 98% for lipid-lowering drugs, 17% for CCBs, and 27% for nitrates. Obstructive CAD was significantly more prevalent in men (P < 0.025), in cigarette smokers (P < 0.01), and in patients with hypertension, diabetes, or hypercholesterolemia (P < 0.001). Age, race, body mass index, and neck circumference were not significantly different for patients with versus without obstructive CAD.
authors.affiliation: Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Mazar
authors.forename: Barry
authors.initials: B
authors.lastname: Schair
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
authors.forename: Omar
authors.initials: O
authors.lastname: Khalique
authors.forename: Stuart G
authors.initials: SG
authors.lastname: Lehrman
mesh_terms: D000367:Age Factors; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D054059:Coronary Occlusion / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D048909:Diabetes Complications; D004363:Drug Utilization; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D012737:Sex Factors; D012907:Smoking
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors